Artrya Limited (AYA)

Overview

Artrya Limited is a pioneering medical technology enterprise committed to leveraging artificial intelligence (AI) to advance healthcare outcomes. Incorporated in 2018 and with its headquarters located in West Perth, Australia, the company has positioned itself at the forefront of innovation within the medical sector. Artrya’s core mission revolves around the utilization of AI to enhance diagnostic processes, specifically targeting the early detection of coronary artery disease (CAD). By focusing on this critical area of heart health, Artrya aims to significantly impact patient care by enabling earlier and more accurate disease identification, thereby improving the effectiveness of treatment strategies and ultimately saving lives.

Products and Services

• Salix

  Salix is Artrya Limited’s flagship product, emblematic of the company’s innovative use of artificial intelligence in healthcare. This cloud-based software solution represents a significant leap forward in the automatic detection of coronary artery disease. By analyzing images from coronary computed tomography angiography (CCTA), Salix leverages AI algorithms to identify signs of CAD with high precision. The platform streamlines the diagnostic process, making it faster and more efficient by reducing the reliance on manual interpretation and thereby accelerating patient access to necessary care. Artrya’s dedication to integrating advanced technology into healthcare through Salix demonstrates its commitment to improving patient outcomes and advancing the fight against coronary artery disease.